- Trials with a EudraCT protocol (44,359)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
44,359 result(s) found.
Displaying page 342 of 2,218.
EudraCT Number: 2013-003774-27 | Sponsor Protocol Number: BC-180-12 | Start Date*: 2014-01-20 |
Sponsor Name:AlgiPharma AS | ||
Full Title: An open label, randomised, two-way crossover scintigraphic study to investigate lung deposition of radiolabelled OligoG delivered as a dry powder and as a nebulised solution in cystic fibrosis pati... | ||
Medical condition: Cystic fibrosis (CF) is an autosomal, recessive inheritable disease caused by a homozygote defect at the long arm of Chromosome 7. This mutation causes absence or defect of the cystic fibrosis tran... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003790-10 | Sponsor Protocol Number: 1.0 | Start Date*: 2013-10-23 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie | ||
Full Title: DEXMEDETOMIDINE FOR PERIPHERAL NERVE BLOCKADE: A DOSE-FINDING STUDY IN VOLUNTEERS | ||
Medical condition: 24 Volunteers recieve an ultrasound guided ulnar nerve block, and apparted into 4 groups. Group 1 receives 3ml Ropivacaine 0.75% without adjuvants. Group 2-4 receives 3ml Ropivacain 0.75% with thre... | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-006000-30 | Sponsor Protocol Number: ForefootFenta vs.1 | Start Date*: 2009-01-09 | ||||||||||||||||
Sponsor Name:Riika Merivirta | ||||||||||||||||||
Full Title: ”Postoperative pain treatment with fentanyl patch after forefoot surgery/ Jalkateräleikkauksen jälkeinen kivunhoito kipulaastarilla”. | ||||||||||||||||||
Medical condition: The patients will be recruited from 18-75 year old male or female patients undergoing hallux valgus or hallux rigidus surgery. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004461-41 | Sponsor Protocol Number: CR-AIR-007 | Start Date*: 2013-06-27 | |||||||||||||||||||||||||||||||
Sponsor Name:Kiadis Pharma Netherlands B.V. | |||||||||||||||||||||||||||||||||
Full Title: An exploratory, open-label, multicenter study to evaluate the safety and efficacy of ATIR, donor T-lymphocytes depleted ex vivo of host alloreactive T-cells, in patients with a hematologic malignan... | |||||||||||||||||||||||||||||||||
Medical condition: Patients with a hematologic malignancy (AML, ALL, or MDS) who are eligible for a haploidentical HSCT | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) GB (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-004476-19 | Sponsor Protocol Number: PCYC-1117-CA | Start Date*: 2013-01-25 | ||||||||||||||||
Sponsor Name:Pharmacyclics LLC | ||||||||||||||||||
Full Title: An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Ly... | ||||||||||||||||||
Medical condition: An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Ly... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) SE (Completed) BE (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-004483-22 | Sponsor Protocol Number: 35664 | Start Date*: 2013-11-29 | |||||||||||
Sponsor Name:Mental Health Service, Esbjerg | |||||||||||||
Full Title: NACOS - The effect of N-acetylcystein for depressive symptoms in patients with bipolar depression - A double blind randomized placebo-controlled trial with follow up | |||||||||||||
Medical condition: Bipolar depression | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001514-15 | Sponsor Protocol Number: 101SK201 | Start Date*: 2013-11-26 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) on Reducing Infarct Volume in Acute Ischem... | |||||||||||||
Medical condition: Acute Ischemic Stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001549-15 | Sponsor Protocol Number: C0921004 | Start Date*: 2013-09-19 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Pfizer Inc (235 East 42nd Street, New York, New York 10017) | ||||||||||||||||||||||||||||||||||||||
Full Title: The long-term antibody persistence of MenACWY-TT vaccine (PF-06866681) versus Meningitec® or Mencevax® ACWY in healthy adolescents and adults and a booster dose of MenACWY-TT administered 10 years ... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Meningococcal disease | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: FI (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-006099-38 | Sponsor Protocol Number: P-piller102 | Start Date*: 2012-08-06 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Effects of an antiandrogenic oral contraceptive on eating behaviour in women with bulimia – A randomized double blinded, placebo controlled study. | ||
Medical condition: Bulimia nervosa is an eating disorder with a prevalence of about 2% in young women (Fairburn and Beglin, 1990). It is characterized by frequent binge eating episodes and the regular use of inapprop... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-006114-14 | Sponsor Protocol Number: 62326B1658 | Start Date*: 2012-04-17 |
Sponsor Name:Research and Development department | ||
Full Title: “Effects of testosterone on glycaemic control and other Cardiovascular Risk factors in Hypogonadal Men with uncontrolled Type 2 Diabetes: A randomized double – blinded placebo controlled add on tr... | ||
Medical condition: Hypogonadism Type 2 Diabetes Cardiovascular risk | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003927-12 | Sponsor Protocol Number: CHUBX2012/28 | Start Date*: 2014-03-03 | |||||||||||
Sponsor Name:CHU de Bordeaux | |||||||||||||
Full Title: Development of an innovative Gallium 68 radiolabeling of DOTATOC (68Ga-DOTATOC) for PET-CT imaging of neuro-endocrine tumors and preliminary clinical evaluation | |||||||||||||
Medical condition: neuroendocrine tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003941-41 | Sponsor Protocol Number: ABR46374 | Start Date*: 2013-11-07 |
Sponsor Name:Medisch Spectrum Twente | ||
Full Title: Reversibility of pulmonary function after inhaling salbutamol in different doses in standard and forward leaning body posture in asthmatic children | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004033-32 | Sponsor Protocol Number: RADIOMEN | Start Date*: 2013-12-13 |
Sponsor Name:FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA | ||
Full Title: AN OPEN, MONOCENTRIC, NOT CONTROLLED CLINICAL TRIAL TO DEVELOP AND EVALUATE THE CLINICAL APPLICATION OF A NEW BETA PROBE FOR RADIOGUIDED SURGERY IN MENINGIOMA TUMOR | ||
Medical condition: SUBJECTS WITH CONVEXITY MENINGIOMA TUMORS OF NEW DIAGNOSIS | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004076-34 | Sponsor Protocol Number: 7487-CL-0209 | Start Date*: 2014-02-27 | ||||||||||||||||||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. | ||||||||||||||||||||||||||||
Full Title: A phase II open-label rollover study for subjects that have participated in an Astellas sponsored linsitinib trial | ||||||||||||||||||||||||||||
Medical condition: Solid tumors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: CZ (Completed) PL (Completed) GB (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-002272-14 | Sponsor Protocol Number: CDX110-07 | Start Date*: 2013-01-11 | |||||||||||
Sponsor Name:CELLDEX THERAPEUTICS | |||||||||||||
Full Title: An International, Randomized, Double-Blind, Controlled Phase II Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glio... | |||||||||||||
Medical condition: Newly diagnosed, surgically resected, EGFRvIII-positive Glioblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002273-54 | Sponsor Protocol Number: ONO-4053POE003 | Start Date*: 2012-11-06 | |||||||||||
Sponsor Name:Ono Pharmaceutical Co. Ltd. | |||||||||||||
Full Title: A randomised, double-blind, placebo controlled, double dummy, four period crossover study to evaluate the efficacy, safety and tolerability of oral repeat doses of ONO-4053 and Cetirizine in subjec... | |||||||||||||
Medical condition: Allergic Rhinitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005703-33 | Sponsor Protocol Number: MOR-006 | Start Date*: 2012-06-19 | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc. | |||||||||||||
Full Title: A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation | |||||||||||||
Medical condition: Mucopolysaccharidosis Type IVA | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000241-39 | Sponsor Protocol Number: BAY86-9766/16728 | Start Date*: 2013-07-26 |
Sponsor Name:Bayer HealthCare AG | ||
Full Title: A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in combination with sorafenib as first line treatment in patients with RAS mutant Hepato... | ||
Medical condition: KRAS or NRAS mutant unresectable or metastatic Hepatocellular carcinoma (HCC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) CZ (Completed) GB (Completed) DE (Completed) BE (Completed) IT (Completed) HU (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-002521-27 | Sponsor Protocol Number: 8477-CL-0020 | Start Date*: 2014-05-08 | ||||||||||||||||
Sponsor Name:Astellas Pharma Europe B.V. (APEB) | ||||||||||||||||||
Full Title: A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects with Peripheral Neuropathic Pain | ||||||||||||||||||
Medical condition: Peripheral Neuropathic Pain | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) CZ (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-002535-24 | Sponsor Protocol Number: BIOS-13-005 | Start Date*: 2013-09-20 |
Sponsor Name:Ethicon Inc., a Johnson & Johnson Co. | ||
Full Title: A Phase III Randomized, Controlled, Superiority Study Evaluating EVARREST™ Fibrin Sealant Patch Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Hepatic Surgery | ||
Medical condition: Subjects undergoing elective, open, hepatic surgery during which a resection plane is created and wherein an appropriate Target Bleeding Site is identified | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
